Abstract: Metabolic reprogramming has been regarded as an essential component of malignant transformation. However, the clinical significance of metabolic heterogeneity remains poorly characterized.
INTRODUCTION
P apillary thyroid cancer (PTC) is the most common endocrine malignancy whose incidence is rapidly increasing worldwide. 1 However, the treatment strategy of PTC is controversial because patients with PTC have widely different prognoses. 2 On one hand, an observational study suggested that a watch-and-wait policy may be sufficient to manage patients with small PTCs. 3, 4 On the other hand, persistent or recurrent PTC occurs in around 10% to 15% of the cases. 5 Moreover, as the survival rate of persistent or recurrent PTC is around 50% to 70%, a significant proportion of PTC cases are fatal. 6 Many investigators have carried out laboratory and clinical studies with the aim of finding new markers to predict the presence of poor prognostic factors such as extrathyroidal extension (ETE) or lymph node metastasis (LNM) to characterize persistent or recurrent PTC at initial diagnosis. In this regard, the v-Raf murine sarcoma viral oncogene homolog B (BRAF) V600E mutation, galectin-3, and human mesothelial cell 1 are all considered potential candidates for the prediction of prognosis. 1, [7] [8] [9] [10] Nonetheless, the clinical applications of these molecular markers are still limited.
Metabolic reprogramming is an essential component of malignant transformation. Following the discovery of the Warburg effect, cancer cells were shown to produce energy predominantly through higher glycolytic activity (glycolytic phenotype) rather than through oxidative phosphorylation (OxPhos) using the electron transport chain (ETC). [11] [12] [13] However, in addition to aerobic glycolysis (Warburg effect), glutamine addiction, somatic isocitrate dehydrogenase mutations, glycine/serine addiction, and the reverse Warburg effect suggested the existence of diverse metabolic phenotypes in cancer cells. [14] [15] [16] [17] [18] In addition, cancer cells generating cellular adenosine triphosphate (ATP) through OxPhos (oxidative phenotype) have been observed. 19, 20 Taken together, these studies indicate substantial intertumor heterogeneity with respect to cell metabolism, although the mechanism of action and clinical implications of the different metabolic phenotypes are not well characterized.
Herein, we carried out gene set enrichment analysis (GSEA) using public repository data combined with reverse transcription polymerase chain reaction (RT-PCR) verification in a cohort of primary tumors to shed light on metabolic heterogeneity in PTC. We also determined if expression of OxPhos-related genes and mitochondrial ribosomal proteins (MRPs) could be used to identify metabolic phenotypes. In addition, gene network analysis and immunohistochemical staining data of OxPhos-related proteins and MRPs available at the Human Protein Atlas (HPA) were also analyzed. Based on functional analysis using thyroid cancer cell lines, both cell lines and primary tumors were classified as either having a glycolytic phenotype or a combined (glycolytic and oxidative) phenotype. Moreover, the metabolic phenotype according to OxPhos amount could be inferred by measuring the expression of MRP L44 (MRPL44) messenger RNA (mRNA). Interestingly, expression of MRPL44 was associated with the presence of LNM, which suggests that it may be a useful clinical marker for predicting poor prognosis and planning the extent of surgery.
METHODS

Subjects and Clinical Data
This study enrolled 103 patients (20 males and 83 females) undergoing thyroidectomy for classical PTC between January 2012 and December 2013 at Severance Hospital, Yonsei Cancer Center, Seoul, Korea. The study size was calculated by Webbased Sample Size/Power Calculations (http://www.stat.ubc.ca/ $rollin/stats/ssize/). All samples were microscopically dissected at the time of surgery after confirmation of diagnosis using frozen sections. Samples were taken from the central portion of the tumor and from contralateral normal tissue. On histological examination, cellularity was >90%. Slides stained with hematoxylin and eosin were reviewed independently by 2 pathologists and a histological diagnosis was made according to the WHO classification. Patient information and clinicopathological parameters were analyzed. All protocols were approved by the institutional review board of Severance Hospital.
RNA Isolation and RT-PCR
Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA), and complementary DNA (cDNA) was prepared from total RNA using M-MLV reverse transcriptase (Invitrogen) and oligo-dT primers (Promega, Madison, WI). RT-PCR was performed on cDNA using the Solg 2X PCR Smart mix Kit (Solgent, Daejeon, South Korea). Genes were amplified using the following primers: reduced nicotinamide adenine dinucleotide (NADH) dehydrogenase (ubiquinone) 1 b subcomplex, 
Public Data and Statistical Analysis
Microarray data from the Gene Expression Omnibus of NCBI (gene expression data available at www.ncbi.nlm.nih.-gov/projects/geo; accession no. GSE6004 and GSE33630) were subjected to GSEA. Analysis of public repository data was performed using the HPA (http://www.proteinatlas.org/) and GeneNetwork (a free scientific web resource, http://www.genenetwork.org/). Statistical analysis was carried out using SPSS version 18.0 for Windows (SPSS Inc, Chicago, IL) or GraphPad Prism (GraphPad Software, Inc, San Diego, CA). Average means were compared with a Mann-Whitney U test. Data are presented as mean AE SD. All P values are 2 sided.
Cell Culture, Oxygen Consumption Rate, and ECAR HELA, BCPAP, TPC1, HTH-7, and XTC.UC1 cells were cultured in Dulbecco modified Eagle medium (DMEM, Life Technologies, Carlsbad, CA) or Roswell Park Memorial Institute medium (Life Technologies) containing 4.5 g/L glucose, 10% fetal calf serum, 0.1 mM NEAA, and 50 mg/mL gentamicin at 378C in a 5% CO 2 atmosphere. 21 The mitochondrial oxygen consumption rate (OCR) was measured using a Seahorse XF-96 extracellular flux analyzer (Seahorse Bioscience Inc, North Billerica, MA). 22, 23 On the day before the experiment, the sensor cartridge was placed in the calibration buffer supplied by Seahorse Bioscience and incubated at 378C without CO 2 . Cells were cultured on Seahorse XF-24 plates at a density of 20,000 cells per well, washed, and incubated with assay medium (DMEM without bicarbonate) at 378C without CO 2 for 1 hour. All media and injection reagents were adjusted to pH 7.4 on the day of the assay. Three baseline measurements of the OCR and ECAR were taken.
Isolation of Mitochondria and BN-PAGE
Isolation of mitochondria and blue native (BN) BN-PAGE was performed as described previously using the NativePAGE Novex Bis-Tris Gel system (Invitrogen). 24 Briefly, cells were homogenized in isolation buffer B (210 mM Mannitol, 70 mM sucrose, 1 mM EGTA, 5 mM HEPES, pH 7.2) with a Teflonglass homogenizer. The homogenate was then centrifuged at 600Âg for 10 minutes at 48C, and the resulting supernatant was recentrifuged at 17,000Âg for 10 minutes at 48C. The mitochondrial fractions, which were recovered in the pellet, were washed with buffer B and resuspended in the same buffer. Mitochondria were either used immediately or stored at À808C for later use. Isolated mitochondria (50 mg) were solubilized using NativePAGE sample buffer with 0.5% n-dodecylb-D-maltoside or 1% digitonin (Invitrogen). The suspensions were centrifuged at 20,000Âg for 10 minutes at 48C. The resulting supernatants were loaded onto a NativePAGE Novex 3% to 12% Bis-Tris gel (Invitrogen). After the run was complete, the gel was transferred to a PVDF membrane using the iBlot Gel Transfer System (Invitrogen). The membrane was fixed with 8% acetic acid. After overnight drying, the membrane was destained with methanol. To detect the OxPhos complex, the Mitoprofile Total OXPHOS Rodent WB Antibody Cocktail, Abcam, Cambridge, MA, USA (Mitosciences/ Abcam) was used. After incubation in the primary antibody dilution, the membrane was washed and visualized using the WesternBreeze Chromogenic Western Blot Immunodetection Kit (Invitrogen).
RESULTS
Metabolic Heterogeneity According to mRNA Expression of OxPhos Proteins and MRPs in PTC
To confirm the heterogeneity of mRNA expression of OxPhos and MRPs in PTC, we performed GSEA using public repository data. In the analysis using GSE33630 (n ¼ 105), both the OxPhos gene set (P ¼ 0.0395, false discovery rate (FDR) q value ¼ 0.225, Figure 1A ) and the MRP gene set (P ¼ 0.0022, FDR q value ¼ 0.001, Figure 1B) showed statistically significant enrichment in normal thyroid tissues. In addition, in the analysis using GSE6004 (n ¼ 18), the OxPhos and MRP gene sets were consistently enriched in normal thyroid tissues (P ¼ 0.0388, FDR q value < 0.05; P ¼ 0.002, FDR q value < 0.01, respectively; Supplementary Figure 1A ATP6V1G2  COX7A1  ATP4A  SDHD  ATP5G1  NDUFA5  NDUFB7  NDUFB2  COX15  NDUFB3  COX17  SDHB  ATP6V1H  SDHC  NDUFA1  NDUFA7  COX8A  ATP5H  ATP6V0D1  ATP5G3  UQCRFS1  UQCRC2  NDUFC1  COX10  LHPP  ATP5B  NDUFV1  NDUFB5  NDUFS4  CYC1  ATP5A1  NDUFS3  NDUFA10  NDUFA2  NDUFA8  ATP5O  ATP5G2  NDUFB6  NDUFB1  ATP6V1E2  ATP5F1  NDUFV3  COX5B  NDUFB9  ATP5D  SDHA  NDUFS7  COX11  ATP5J  ATP6V1C1  COX7B  NDUFA3  COX7A2  ATP5C1  COX7C  ATP6V1G1  NDUFV2  COX6A1  NDUFA6  COX6C  NDUFS1  ATP6V1D  NDUFC2  NDUFA11  NDUFB10  NDUFB8  ATP6V0B  ATP6V0A1  COX4I1  UQCRH  COX7A2L  PPA1  ATP5L  NDUFS2  ATP5I Enrichment score 0.5061085
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Metabolic Phenotype in Thyroid Cancer Cell Lines
Considering the differential expression of OxPhos and MRP genes, we postulated that a certain degree of ''metabolic diversity'' exists in PTCs. To investigate this possibility, we estimated OCR and ECAR in HELA cells and thyroid cancer cell lines using an XF analyzer. As shown in Figure 3A and B, HELA cells showed a higher OCR and a lower ECAR compared with most thyroid cancer cell lines, suggesting that they generate more ATP via OxPhos (oxidative phenotype) than via glycolysis. BCPAP cells, a BRAF V600E positive PTC cell line, showed a decreased OCR and the highest ECAR, which was in agreement with the higher levels of glycolysis (glycolytic phenotype) in this cell line. TPC1 cells, a PTC cell line harboring a RET/PTC1 rearrangement, had relatively lower levels of both OCR and ECAR, suggesting that this cell line had the lowest metabolic rate (metabolically inactive). Interestingly, HTH-7 cells, an ATC cell line, showed increased OCR and ECAR, suggesting that this cell line generates its ATP via both glycolysis and OxPhos (combined phenotype). XTC.UC1 cells, derived from a Hurthle cell cancer harboring mutations in mitochondrial DNA (mtDNA), had a lower OCR and a higher ECAR, as expected (glycolytic phenotype). In BN-PAGE, HELA cells had the most abundant OxPhos complexes ( Figure 3C ), whereas complex IV was barely detectable in TPC1 cells ( Figure 3C, lower panel) . Consistent with the results obtained using the XF analyzer, HTH-7 cells contained more intact OxPhos complexes than TPC1 cells. Thus, the thyroid cancer cell lines displayed substantial metabolic diversity. The classification of thyroid cancer cell lines according to metabolic phenotype is shown in Figure 3D .
Heterogeneous Expression of OxPhos and MRPs in PTC
Based on the results obtained using public repository data, RT-PCR was performed using mRNA from primary PTC and matched normal tissues to determine the expression status of OxPhos and MRP genes. First, 12 patients whose preoperative [ Based on the heterogeneous expression of MRPL44 and NDUFA5, RT-PCR for MRPL44 was performed in 103 primary PTC and matched normal thyroid tissue. Of these, 87 PTCs (84.5%) showed a reduction in MRPL44 expression compared with that in normal tissue, whereas 16 PTCs (15.5%) showed no differences in MRPL44 mRNA expression between tumoral and normal tissues (data not shown). Interestingly, clinicopathological analysis indicated that regional LNM, including lateral neck node metastasis (N1b), was more frequent in PTCs that exhibited no change in expression of MRPL44 mRNA (P ¼ 0.001, Table 1 ). Moreover, multivariate analysis clearly indicated that no change in MRPL44 expression (indicated as Group 2) increased the risk of lateral neck LNM after adjustment for age, ETE, T-stage, and multifocality (odds ratio 9.267, 95% confidence interval 1.852-46.371, P ¼ 0.007, Table 2 ).
DISCUSSION
Otto Warburg 11 discovered that most cancer cells produce cellular ATP using a high rate of glycolysis instead of OxPhos. This observation can be clinically detected by performing uptake imaging using FDG PET as shown in Figure 4B . The Warburg effect might be related to mitochondrial damage in cancer cells, or to adaptation to hypoxia within the tumor microenvironment. Recently, the aberrant expression of glycolytic enzymes, such as overexpression of mitochondrial bound hexokinase and the M2 splice isoform of pyruvate kinase, was reported as a possible cause of the Warburg effect. 25, 26 However, because mitochondria can produce much more cellular ATP via OxPhos than via glycolysis, cancer cells still use mitochondria to produce ATP for fatty acid synthesis and other biosynthetic processes. 20 In agreement with these recent observations concerning mitochondrial metabolism in cancer cells, the GSEA data showed that OxPhos and MR gene sets are coordinately downregulated in most PTCs, indicating that PTC cells rely primarily on aerobic glycolysis for their energy needs. However, 16.3% of PTCs in the GSE33630 data set and 15.5% of PTCs in our cohort had the same amount of OxPhos and MRP mRNA expression as normal thyroid tissues. In line with our data, HPA also indicated that MRPL44 and NDUFA5 
expression in a proportion of PTCs was similar to that in normal thyroid tissues.
Proteins in the ETC originate from both nuclear DNA (nDNA-encoded) and mtDNA (mtDNA-encoded). 27 Because of the different origins of proteins in the ETC, nDNA-encoded ETC proteins synthesized in the cytosol become localized to mitochondrial matrix via a translocase on the outer mitochondrial membrane and a translocase on the inner mitochondrial membrane complexes. 28 After translocation, nDNA-encoded ETC proteins undergo an assembly process with mtDNAencoded ETC proteins to generate an intact OxPhos complex. 29 During this process, transcription and translation processes from mtDNA must be coordinated with cytosolic synthesis, transport, and assembly of nDNA-encoded ETC proteins. 30 For this reason, we found a strong positive correlation between MRPs and ETC proteins in the results of our correlation assay and gene network analyses (Figure 2) , which support our hypothesis that MRPL44 is a representative marker of OxPhos.
HELA cells are used as a control cell line for the oxidative phenotype because they have abundant mitochondria, 31 whereas XTC.UC1 cells, originating from a Hurthle cell cancer, are used as representatives of the glycolytic phenotype. 32 As expected, HELA cells had the highest OCR and the lowest ECAR, whereas XTC.UC1 had the lowest OCR and the highest ECAR. BCPAP cells, a BRAF V600E -positive PTC cell line, had the glycolytic phenotype. However, HTH-7, which is a cell line derived from an ATC, had a high OCR and a high ECAR, indicating that although these cells rely on glycolysis, they also use oxidative respiration (combined oxidative and glycolytic phenotype). In support of the results of the functional analysis using the XF analyzer, BN-PAGE also showed differences in the amounts of OxPhos complexes between TPC1 (metabolically inactive in our study) and HTH-7 cells. Based on these observations, we hypothesize that PTCs and thyroid cancer cell lines can be separated into 2 groups with distinct metabolic phenotypes, namely, a glycolytic phenotype group and a combined (oxidative and glycolytic) phenotype group.
One of the most interesting findings in the present study is that MRPL44 expression correlates with the presence of LNM. The expression of MRPL44 can be used to identify the metabolic phenotype in PTC; low expression indicates a glycolytic phenotype, whereas high expression indicates a combined phenotype. PTC with a combined metabolic phenotype, indicated by a high level of MRPL44 expression and a high FDG uptake, might have a growth advantage because of the high amounts of ATP and abundant precursors of fatty acid synthesis produced. However, because a functional assay using primary PTC cells was not performed, we cannot definitively conclude that the ETC functions properly in PTCs with abundant MRPL44 expression. In addition, we did not investigate other factors that affect metabolism, such as glutamine addiction, somatic isocitrate dehydrogenase mutations, or glycine/serine addiction in PTCs. These limitations will be explored in future studies.
In conclusion, our data suggest that a proportion of PTCs have a combined (oxidative and glycolytic) metabolic phenotype, even though they still rely on glycolytic activity for ATP generation. In addition, the metabolic phenotype can be determined by measuring the expression of MRPL44, which we show to be a promising marker for the prediction of lateral neck LNM. Future studies should focus on the metabolic phenotyping of PTCs according to their level of MRPL44 expression. www.md-journal.com | 7
